Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
| Catalog No. | Product Name | Size | List Price (US$) | Quantity |
|---|
The research grade Spartalizumab biosimilar protein is for research use only. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Price/availability/specifications subject to change without notice. Unless otherwise indicated, our catalog and customized products are for research use only and not intended for human or animal diagnostic or therapeutic use.
Phone: 1-617-401-8149
Fax: 1-617-606-5019
Email: message@sydlabs.com
Or leave a message with a formal purchase
order (PO) Or credit card.
Recombinant Humanized IgG4 Monoclonal Antibody.
Isotype: Human IgG4 kappa.
Source: The anti-human PD-1 monoclonal antibody spartalizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade spartalizumab biosimilar specifically binds to the programmed cell death protein 1 (PD-1), antagonizing its interaction with its known ligands PD-L1 and PD-L2.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by spartalizumab.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 0.1 EU per 1 ug of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The research grade spartalizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Background
Spartalizumab Biosimilar uses the same protein sequences as the therapeutic antibody spartalizumab. A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.
Syd Labs provides the following research grade anti-PD-L1 / PD-1 antibody biosimilar proteins:
Atezolizumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Avelumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Camrelizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Cemiplimab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Durvalumab biosimilar, research grade, anti-human PD-L1 monoclonal antibody
Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
Spartalizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody
PD-1 is a member of the extended CD28/CTLA-4 family of T cell regulators. Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Copyright © 2009-2020 sydlabs.com. All rights reserved.
Use of this website means that you have read, understood, and accepted the Syd Labs Privacy Policy and Terms & Conditions.